Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
Top Cited Papers
- 1 January 2009
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 4 (1), 97-101
- https://doi.org/10.1097/jto.0b013e318191520c
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium StudyClinical Cancer Research, 2008
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid TumorsClinical Cancer Research, 2008
- Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancerInternational Journal of Cancer, 2007
- Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancerInvestigational New Drugs, 2007
- The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivoJournal of Translational Medicine, 2007
- Potential Role of Histone Deacetylase Inhibitors in Mesothelioma: Clinical Experience with Suberoylanilide Hydroxamic AcidClinical Lung Cancer, 2006
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signalingOncogene, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989